{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:04:14Z","timestamp":1784347454501,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114\\u20132314-B-016\\u2013009 -MY3"],"award-info":[{"award-number":["NSTC 114\\u20132314-B-016\\u2013009 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST111\\u20132314-B-016\\u2013042-MY3"],"award-info":[{"award-number":["MOST111\\u20132314-B-016\\u2013042-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016292","name":"National Applied Research Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022871","name":"National Defense Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["NDMC-111\\u20138"],"award-info":[{"award-number":["NDMC-111\\u20138"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["MND-MAB-110\\u2013137"],"award-info":[{"award-number":["MND-MAB-110\\u2013137"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMNDMC11013TSGH C03\\u2013113,036"],"award-info":[{"award-number":["CMNDMC11013TSGH C03\\u2013113,036"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["TSGH C02\\u2013112,028"],"award-info":[{"award-number":["TSGH C02\\u2013112,028"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018422","name":"National Laboratory Animal Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106803","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:48:56Z","timestamp":1760546936000},"page":"106803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An innovative AQP4 loop C-targeted monoclonal antibody reduces complement-dependent cytotoxicity and lessens experimental neuromyelitis optica"],"prefix":"10.1016","volume":"104","author":[{"given":"Kai-Chen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Wan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheih-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu-Jiun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Te","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Fen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huey-Kang","family":"Sytwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-9692","authenticated-orcid":false,"given":"Shyi-Jou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2025.106803_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/biom12040591","article-title":"Aquaporin-4 in neuromyelitis optica spectrum disorders: a target of autoimmunity in the central nervous system","volume":"12","author":"Abe","year":"2022","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.msard.2025.106803_bib0002","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbamem.2017.05.001","article-title":"Comparative molecular dynamics study of neuromyelitis optica-immunoglobulin G binding to aquaporin-4 extracellular domains","volume":"1859","author":"Alberga","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"5","key":"10.1016\/j.msard.2025.106803_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106803_bib0005","first-page":"7","article-title":"Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors","volume":"81","author":"Chin","year":"1994","journal-title":"Immunology"},{"issue":"51","key":"10.1016\/j.msard.2025.106803_bib0006","doi-asserted-by":"crossref","first-page":"35850","DOI":"10.1074\/jbc.M109.071670","article-title":"Live cell analysis of aquaporin-4 m1\/m23 interactions and regulated orthogonal array assembly in glial cells","volume":"284","author":"Crane","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.msard.2025.106803_bib0007","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1084\/jem.20022232","article-title":"A role for complement in feedback enhancement of antibody responses by Igg3","volume":"197","author":"D\u00edaz de St\u00e5hl","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2025.106803_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107827","article-title":"Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders","volume":"162","author":"Duan","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4049\/jimmunol.160.1.20","article-title":"Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity","volume":"160","author":"Gavin","year":"1998","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.msard.2025.106803_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of igg binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106803_bib0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-3083.2005.01684.x","article-title":"IgG3-mediated enhancement of the antibody response is normal in fc gammari-deficient mice","volume":"62","author":"Hjelm","year":"2005","journal-title":"Scand. J. Immunol."},{"issue":"119","key":"10.1016\/j.msard.2025.106803_bib0012","doi-asserted-by":"crossref","DOI":"10.3791\/54832","article-title":"Generation of murine monoclonal antibodies by hybridoma technology","author":"Holzl\u00f6hner","year":"2017","journal-title":"J. Vis. Exp."},{"issue":"7","key":"10.1016\/j.msard.2025.106803_bib0014","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)\u2013revised recommendations of the neuromyelitis optica study group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2013revised recommendations of the neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106803_bib0016","first-page":"3","article-title":"Preparing serum for functional complement assays. [Technical note]","volume":"352","author":"Lachmann","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.msard.2025.106803_bib0017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.msard.2019.02.025","article-title":"Repetitive intrathecal injection of human NMO-IgG with complement exacerbates disease severity with NMO pathology in experimental allergic encephalomyelitis mice","volume":"30","author":"Lee","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106803_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.msard.2025.106803_bib0019","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1073\/pnas.93.20.10908","article-title":"The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain","volume":"93","author":"Lu","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2025.106803_bib0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0021","first-page":"12","article-title":"High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, Nmo-Igg","volume":"173","author":"Miyazaki-Komine","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"34","key":"10.1016\/j.msard.2025.106803_bib0022","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1021\/bi990941s","article-title":"Heterotetrameric composition of aquaporin-4 water channels","volume":"38","author":"Neely","year":"1999","journal-title":"Biochemistry"},{"issue":"19","key":"10.1016\/j.msard.2025.106803_bib0023","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1074\/jbc.M115.647149","article-title":"Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica igg","volume":"290","author":"Owens","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.msard.2025.106803_bib0024","doi-asserted-by":"crossref","first-page":"9216","DOI":"10.1074\/jbc.M110.123000","article-title":"Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding","volume":"286","author":"Pisani","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.msard.2025.106803_bib0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2025.106803_bib0026","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1089\/mab.2013.0007","article-title":"A novel monoclonal antibody against the c-terminal region of aquaporin-4","volume":"32","author":"Ramadhanti","year":"2013","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"issue":"5","key":"10.1016\/j.msard.2025.106803_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"52","key":"10.1016\/j.msard.2025.106803_bib0028","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","article-title":"Evidence against cellular internalization in vivo of nmo-igg, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica","volume":"286","author":"Ratelade","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.msard.2025.106803_bib0029","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/brain\/awab465","article-title":"Next-generation antibody-based therapies in neurology","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2025.106803_bib0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molimm.2014.06.010","article-title":"How antibodies use complement to regulate antibody responses","volume":"61","author":"S\u00f6rman","year":"2014","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0031","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0022-1759(84)90387-9","article-title":"Intrasplenic primary immunization for the production of monoclonal antibodies","volume":"70","author":"Spitz","year":"1984","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.msard.2025.106803_bib0032","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/imt.11.4","article-title":"Hybridoma technologies for antibody production","volume":"3","author":"Tomita","year":"2011","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","article-title":"Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica","volume":"134","author":"Tradtrantip","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01294-3","article-title":"Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder","volume":"9","author":"Tradtrantip","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.msard.2025.106803_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ana.22657","article-title":"Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106803_bib0036","doi-asserted-by":"crossref","unstructured":"UniProt: the Universal Protein Knowledgebase in 2025. (2025). Nucleic Acids Res., 53(D1), D609-d617, doi:10.1093\/nar\/gkae1010.","DOI":"10.1093\/nar\/gkae1010"},{"key":"10.1016\/j.msard.2025.106803_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106311","article-title":"Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders","volume":"95","author":"Vieira","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106803_bib0038","first-page":"343","article-title":"Neuromyelitis optica: clinical syndrome and the nmo-igg autoantibody marker","volume":"318","author":"Weinshenker","year":"2008","journal-title":"Curr. Top Microbiol. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106803_bib0039","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 igg-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106803_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im0205s102","article-title":"Production of monoclonal antibodies","volume":"102","author":"Yokoyama","year":"2013","journal-title":"Curr. Protoc. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106803_bib0041","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1203\/00006450-200009000-00012","article-title":"Identification of a new form of AQP4 mrna that is developmentally expressed in mouse brain","volume":"48","author":"Zelenin","year":"2000","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.msard.2025.106803_bib0042","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-61779-931-0_7","article-title":"Hybridoma technology for the generation of monoclonal antibodies","volume":"901","author":"Zhang","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.msard.2025.106803_bib0043","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","article-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","volume":"123","author":"Zhang","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2025.106803_fur1","first-page":"77","article-title":"The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis","volume":"7","author":"Huang","year":"2016","journal-title":"Biochem. Biophys. Rep."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:37:37Z","timestamp":1784345857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"alternative-id":["S2211034825005450"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106803","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An innovative AQP4 loop C-targeted monoclonal antibody reduces complement-dependent cytotoxicity and lessens experimental neuromyelitis optica","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106803"}}